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Immunological biomarkers predict HIV-1 viral
rebound after treatment interruption
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Treatment of HIV-1 infection with antiretroviral therapy (ART) in the weeks following
transmission may induce a state of ‘post-treatment control’ (PTC) in some patients, in whom
viraemia remains undetectable when ART is stopped. Explaining PTC could help our
understanding of the processes that maintain viral persistence. Here we show that
immunological biomarkers can predict time to viral rebound after stopping ART by analysing
data from a randomized study of primary HIV-1 infection incorporating a treatment
interruption (TI) after 48 weeks of ART (the SPARTAC trial). T-cell exhaustion markers PD-1,
Tim-3 and Lag-3 measured prior to ARTstrongly predict time to the return of viraemia. These
data indicate that T-cell exhaustion markers may identify those latently infected cells with a
higher proclivity to viral transcription. Our results may open new avenues for understanding
the mechanisms underlying PTC, and eventually HIV-1 eradication.
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A
ntiretroviral therapy (ART) for the treatment of Human
Immunodeﬁciency Virus Type 1 (HIV-1) infection has
dramatically improved survival1–3, but is not a cure—a
consequence of a reservoir of latently infected cells4. Primary
HIV-1 infection (PHI)—the period within weeks to months of
seroconversion—may provide insights into how this reservoir is
activated and whether it can be suppressed, as stopping ART
initiated in this early stage has in certain patients been associated
with periods of aviraemic remission5—in some cases for over 10
years6. Post hoc analyses of other larger PHI cohorts support
this phenomenon of sustained post-treatment control (PTC)7,8,
as well as periods of transient aviraemic remission5.
The mechanisms that induce and maintain this remissive state
of PTC remain unclear. There is debate over whether the timing
of viral rebound after stopping ART is a random, stochastic
process based on the spontaneous re-awakening of HIV-1 in
latently infected T lymphocytes, or whether the host—for
example, through HIV-1-speciﬁc or innate immunity—is the
determining factor. In the best characterized cohort to date
(VISCONTI), PTC was associated with low (but detectable)
reservoirs, almost non-existent HIV-speciﬁc immune responses,
an absence of protective HLA Class I alleles and highly
symptomatic seroconversion illnesses6—a distinct phenotype
from the more widely recognised examples of spontaneous
viraemic control shown by ‘elite controllers’9. The SPARTAC
trial10 was a randomized controlled trial (RCT) comparing ART
for either 48 or 12 weeks relative to standard of care in adults with
PHI. We reported prolonged periods of aviraemia post-treatment
interruption (TI) in participants allocated to receive ART for 48
weeks—14% had undetectable plasma viral loads 1 year after
stopping ART5. Total HIV-1 DNA level at baseline and week 48
was associated with shorter time to viral rebound11.
Here we report an analysis of immunological and virological
factors from SPARTAC to explore those that either associate with
HIV-1 DNA levels or independently predict viral rebound on
stopping ART. We ﬁnd that pre-therapy measures of T-cell
exhaustion (PD-1, Tim-3 and Lag-3) were statistically signiﬁcant
predictors of virological rebound, suggesting that these markers
should be considered in future algorithms used to detect PTC.
Results
SPARTAC trial participant characteristics. About 154 partici-
pants recruited to the SPARTAC trial12 were studied based on
infection with subtype B HIV-1 and sample availability. SPARTAC
incorporated a randomly allocated TI after 48 weeks of ART
in a third of patients, providing a unique opportunity to study
determinants of rebound. The demographics of the 154 participants
are shown in Supplementary Table 1. All 154 patients were sampled
for HIV-1 DNA levels at enrolment at the pre-therapy baseline
(week 0), a median of 74 days from the estimated date of HIV-1
seroconversion. Of these (due to sample limitations), 78 were
also assayed for immunological markers of T-cell exhaustion
and activation (Supplementary Table 1). Participants who were
randomized to receive 48 weeks of ART, and for whom samples
were available at the point of stopping ART, (n¼ 47;
Supplementary Table 1) were studied in analyses of TI.
Selection of biomarkers. We devised a panel of 18 biomarkers to
measure parameters of host immunity and markers of the HIV-1
reservoir (Table 1). We wished to determine associations with
levels of HIV-1 DNA levels and assess whether the biomarkers
might also independently predict rebound at TI. At baseline,
biomarker assays were carried out on up to 154 patients (not all
assays were conducted on all patients—Table 1 for breakdown).
At the point of TI after 48 weeks of ART, 47 participants were
available for analysis. Again, and due to sample availability, not
all biomarkers were tested on all patients (Table 1).
T-cell immunity correlates with HIV-1 DNA at seroconversion.
To determine the relationship between the HIV-1 reservoir and
HIV-1-speciﬁc T-cell immunity prior to therapy, we studied
HIV-1 Gag-directed T-cell responses by ELISpot. Participants
who made a CD4 T-cell ELISpot response had signiﬁcantly lower
mean HIV-1 DNA levels compared with those who did not
(Fig. 1a; for total DNA P¼ 0.018 (3.77 versus 4.01 log10 copies,
respectively) and for Integrated P¼ 0.046 (3.44 versus 3.72 log10
copies, respectively; t-test). Total (and to a lesser extent
Integrated) HIV-1 DNA was inversely correlated with numbers
of HIV-1 Gag-speciﬁc CD8 T-cell responses (P¼ 0.046;
b¼  0.064; s.e. 0.032 and P¼ 0.081, respectively; linear
regression; Fig. 1b).
We then looked for associations with HLA Class I, the only
consistent genetic association with HIV-1 progression13. For each
HLA Class I allele in our cohort, the median value of Total HIV-1
DNA was calculated (numbers contributing to each HLA allele are
in Supplementary Table 2). In Fig. 1c, HLA alleles were categorized
as protective (red) or associated with rapid progression (blue)
based on well-characterized associations with HIV-1 progression14.
While individual favourable (for example, B*27 and B*57) and
progressive (for example, B*35 and B*08) HLA Class I alleles were
associated signiﬁcantly with lower and higher Total HIV-1 DNA
levels, respectively, we also found that, overall, participants with
protective alleles (n¼ 20) had signiﬁcantly lower mean Total
HIV-1 DNA levels than those with progression-associated alleles
(n¼ 55) (3.46 versus 4.05 log10 HIV-1 DNA copies per million
CD4 T cells; Po0.001 (t-test)) (Fig. 1c).
Co-variation of biomarkers at PHI. Together, these data support
a close interaction between T-cell immunity and the reservoir size
in early HIV infection. An exploratory analysis was therefore
carried out to illustrate co-variation within 17 immunological and
reservoir-associated biomarkers, which were available at the
baseline pre-therapy time-point. Results are presented graphically
using a ‘correlogram’15 (Fig. 2) in which the order in which the
variables are presented was determined by hierarchical clustering
with optimal leaf ordering16. The heat map (lower triangle of the
correlogram) indicates the direction (blue indicates a positive
association and red indicates a negative association) and the
strength of the correlation (intensity of colour). The same
information is also conveyed in the series of pie charts (upper
triangle), where the strength of the correlation is indicated by
both the size of the pie slice and intensity of colour.
In Fig. 2, the correlogram shows negative associations between
CD4 T-cell count and all markers of viral nucleic acid and immune
function (except IL-6). PD-1, CD38 and HLA-DR expression on
CD4 and CD8 T cells, as represented by the deeper blue shaded
region, cluster together with similar positive correlations. The
correlogram shows that eight immunological variables: D-dimer,
Lag-3 (CD8 only), HLA-DR (CD4, CD8), PD-1 (CD4, CD8),
CD38 (CD4, CD8), showed the strongest correlations with Total
HIV-1 DNA and were selected for further analysis.
Correlates of Total HIV-1 DNA pre-ART and at TI. As Total
HIV-1 DNA was a predictor of time to plasma viral load (VL)
rebound in SPARTAC11, we wished to explore the joint
association of these biomarkers with HIV-1 DNA in a
regression analysis. In addition to the eight variables identiﬁed
in the correlation analysis, we included three clinical markers
associated with HIV-1 DNA: plasma VL, CD4 T-cell count and
CD4/CD8 T-cell ratio, which were also evident in the
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correlogram. Plasma VL, CD4 T-cell count and CD4/CD8 ratio
were all associated signiﬁcantly (Po0.001; linear regression) with
HIV-1 DNA levels, although in multivariable models (adjusting
for just these measures) the CD4/CD8 ratio was no longer
signiﬁcant (Table 2; Model A). We found strong, signiﬁcant
correlations with biomarkers for CD4 and CD8 T-cell activation
and exhaustion, as well as D-dimer (Table 2, Model B).
In a multivariable model (n¼ 78), CD8 CD38, CD8 Lag-3
and D-dimer retained a signiﬁcant association with HIV-1
Total DNA. (These results are not overly impacted by adjusting
for multiple comparisons (Supplementary Table 3); signiﬁcance
(at Po0.05) was lost for HLA-DR). In a further model
including plasma VL and CD4 T-cell count, the only biomarker
to retain a signiﬁcant association with HIV-1 DNA was CD8
Lag-3 (Table 2, Model C).
Many of the immunological associations present pre-ART
were not preserved following ART. After 48 weeks of ART
(at the point of TI) the only statistical associations with
contemporaneously measured Total HIV-1 DNA were unspliced
cell-associated HIV-1 RNA and percentage HLA-DR on CD4
T cells (Supplementary Table 4).
Predictors of time to plasma HIV-1 viral load rebound. Would
biomarkers associated with HIV-1 DNA also predict time to VL
rebound after TI? Although sample limitation restricted the
analysis of all biomarkers in all 47 patients, we could ﬁnd no
strong evidence for any biomarker (other than Total HIV-1
DNA) measured at TI predicting viral rebound. CD4 T-cell
ELISpots measured at baseline or TI did not predict time to
rebound (Supplementary Fig. 1).
However, pre-therapy levels of T-cell exhaustion were strongly
associated with time to VL rebound4400 copies per ml after TI.
In survival analyses dividing the cohort at median values,
expression on CD4 and CD8 T cells of PD-1 (P¼ 0.00017,
P¼ 0.0013), Tim-3 (P¼ 0.0032, P¼ 0.08) and Lag-3 (P¼ 0.016,
P¼ 0.023), respectively, predicted viral rebound to 400 copies
per ml (log rank test) (Fig. 3a–f). These ﬁndings were supported
by Cox models adjusting for HIV-1 DNA levels (Table 3;
Supplementary Table 5). Adjusting for multiple comparisons
(Supplementary Table 6) had no impact on the signiﬁcance for
PD-1, although Lag-3 expression was no longer signiﬁcant. When
using a VL cut-off for rebound of 50 RNA copies per ml, Tim-3
(Po0.001 for CD4; P¼ 0.0067 for CD8 T cells) and PD-1
(P¼ 0.023 for CD4 T cells) were predictive of time to rebound
(Supplementary Table 7).
No other baseline measures (including markers of activation,
IL-6 and D-dimer) were signiﬁcantly associated with time to
rebound. While PD-1 and Lag-3 correlated with HIV-1 DNA
levels, Tim-3 did not, suggesting a possible separate mechanism
Table 1 | Biomarkers and methods of measurement.
Biomarker ‘class’ Biomarker Sample Assay platform Time-point analysed week (n)
Clinical CD4 cell count Blood Flow cytometry 0 (154)
48 (47)
Plasma viral load Plasma Commercial assay 0 (154)
48 (47)
CD4/CD8 ratio Blood Flow cytometry 0 (154)
48 (47)
Viral DNA HIV-1 DNA (Total) CD4 T cells qPCR 0 (154)
48 (47)
HIV-1 DNA (Integrated) CD4 T cells qPCR 0 (111)
48 (47)
Cell-associated unspliced HIV-1 RNA CD4 T cells qPCR 0 (0)
48 (27)
HIV-1-speciﬁc T-cell immunity CD8 ELISpot CD8 T cells ELISpot 0 (107)
48 (0)
CD4 ELISpot CD4 T cells ELISpot 0 (93)
48 (32)
T-cell activation HLA-DR CD4/CD8 T cells Flow cytometry 0 (89)
48 (40)
CD38 CD4/CD8 T cells Flow cytometry 0 (89)
48 (40)
CD25 CD4/CD8 T cells Flow cytometry 0 (0)
48 (40)
CD69 CD4/CD8 T cells Flow cytometry 0 (0)
48 (40)
T-cell exhaustion PD-1 CD4/CD8 T cells Flow cytometry 0 (78)
48 (37)
Lag-3 CD4/CD8 T cells Flow cytometry 0 (78)
48 (37)
Tim-3 CD4/CD8 T cells Flow cytometry 0 (78)
48 (37)
TIGIT CD4/CD8 T cells Flow cytometry 0 (0)
48 (37)
Soluble markers of immune activation IL-6 Plasma ELISA 0 (143)
48 (42)
D-dimer Plasma ELISA 0 (137)
48 (40)
ELISA, enzyme-linked immunosorbent assay; qPCR, quantitative PCR.
Details of 18 biomarkers studied including tissue source, assay platform and time-point of analysis and total number of participant samples available at each time-point. Not all samples were available at
all time-points.
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of action. When adjusting for other exhaustion markers, Tim-3
expression on CD4 T cells and CD8 T cells was the only marker
retaining signiﬁcance for all comparisons (Supplementary
Table 5). PD-1 and Lag-3 retained signiﬁcance for expression
on CD8 T cells only. Of note, none of PD-1, Tim-3 or Lag-3
predicted time to VL rebound when measured at TI
(Supplementary Table 8). Although all badged as ‘exhaustion
markers’ (or ‘immune checkpoint markers), it is interesting to
note that Tim-3, PD-1 and Lag-3 were predominantly expressed
on separate cells. While all three markers were widely expressed
on their own on CD4 (range 19.93–33.30%) and CD8 (range
15.00–50.29%) T cells, co-expression of any two markers was
limited (Fig. 4).
Discussion
ART in PHI can, in some cases, induce a state of virological
remission or PTC. In the search for a cure for HIV-1 infection, it
is important to understand the underlying mechanisms
that produce PTC and assess the possibility of identifying
patients most likely to achieve PTC using an algorithm of
biomarkers.
The SPARTAC RCT was not designed to identify biomarkers
that predict remission, yet the incorporation of a randomly
allocated TI after 48 weeks of ART provided a unique opportunity
due to the numerous virological and immunological studies
undertaken within the protocol. TI studies have been set back by
the increased mortality witnessed in the SMART study17, yet
newer study designs in which ART is recommenced based on
viral detection in plasma rather than CD4 decline may provide a
safer option. Accordingly, a number of studies are currently being
planned to assess the impact of ART on virological remission
through intensively monitored TIs, with the assessment of
biomarkers being a key endpoint. This analysis of SPARTAC
therefore provides preliminary critical data to help inform future
larger clinical studies and cohorts.
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Figure 1 | HIV-1 DNA is associated with HIV-1-speciﬁc T-cell immunity and HLA class I alleles. HIV-1 DNA levels presented according to whether the
participant made a (a) CD4 or (b) CD8 interferon gamma ELISPOT response to HIV-1 Gag. Grey and white box and whisker plots represent Integrated and
Total HIV-1 DNA, respectively, with diamonds indicating mean values: ‘Integrated No response’ 3.72, ‘Integrated Response’ 3.49, ‘Total No Response’ 4.01,
‘Total Response’ 3.77 log10 copies per million CD4 T cells, respectively. Signiﬁcance determined using (a) t-tests and (b) linear regression. HIV-1 DNA
reported as log10 copies per million CD4 Tcells. Patient numbers: for ‘No Response’ and ‘Response’ for Total (n¼ 33 and 60) and for Integrated (n¼ 27 and
45), respectively. For 0, 1, 2, 3þ CD8þ T-cell responses for Total (n¼ 22, 40, 25 and 20) and Integrated (n¼ 22, 30, 23 and 17), respectively. (c) HLA
Class I alleles ranked according to the median value of Total HIV-1 DNA, presented as box and whisker plots. Red and blue bars represent alleles associated
with HIV-1 control and rapid progression, respectively. The horizontal black line represents the median value of the cohort and the box represents the inter-
quartile range. The whiskers extend to the largest value within 1.5*IQR, with additional data points showing outliers. Patient numbers given in
Supplementary Table 3. 0.01o*Po0.05, 0.001o**Po0.01, ***Po0.0001. Signiﬁcance determined by Mann–Whitney test of target population against the
rest of the patient samples.
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Although no long-term PTC was seen in this group of patients,
we did ﬁnd a prolonged period of aviraemia post TI—1 year after
stopping ART 14% of participants were still undetectable5.
In SPARTAC, Total (but not Integrated) HIV-1 DNA
measurements at baseline and week 48 helped stratify
patients according to their viral-rebound kinetics11. We now
show that—prior to ART—numerous measures of T-cell
immunity (both HIV-1 speciﬁc and non-speciﬁc) measured in
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Figure 2 | Correlogram of baseline virological and immunological variables. Heat maps and pie charts are used to indicate the strength of associations
between potential biomarkers, with ordering determined by hierarchical clustering. Red indicates a negative correlation between the variables, blue a
positive correlation. Size of pie and intensity of the colour indicates the strength of the association. Heat maps for associations with HIV-1 Total DNA are
indicated with the red box.
Table 2 | Biomarkers associated with total HIV-1 DNA at PHI.
A Baseline variable Simple linear model (b; s.e.; P-value)* Multivariable regression model A (b; s.e.; P-value)*
CD4/CD8 T-cell ratio 0.904; 0.15; o0.001 0.002; 0.16; 0.99
CD4 T-cell count  14.9; 0.425; o0.001 8.56; 2.29; o0.001
log10 viral load 4.24; 0.425; o0.001 3.69; 0.52; o0.001
B Simple linear model (b; s.e.; P-value)* Multivariable regression model B (b; s.e.; P-value)*
CD8þ CD38þ w 0.017; 0.003;o0.001 0.012; 0.003;o0.001
CD4þ CD38þ w 0.007; 0.004; 0.055 —z
CD8þ PD-1w 0.057; 0.017; 0.002 —z
CD4þ PD-1w 0.020; 0.014; 0.169 —z
CD8þHLA-DRw 0.010; 0.003; 0.005 —z
CD4þHLA-DRw 0.017; 0.008; 0.041 —z
CD8þ Lag-3w 0.012; 0.004; 0.002 0.019; 0.009; 0.04
D-dimer 0.034; 0.010; o0.001 0.536; 0.236; 0.026
C Multivariable regression model C (b; s.e.; P-value)*
CD4 T-cell count 8.23; 2.04; o0.001
log10 viral load 3.047; 0.45;o0.001
CD8 CD38w 0.002; 0.002; 0.329
CD8 Lag-3w 0.017; 0.007; 0.014
D-dimer 0.28; 0.17; 0.1
PHI, primary HIV-1 infection.
Linear regression models showing associations at baseline with log10 Total HIV-DNA. Model A: N¼ 76, multivariable linear regression model with log10 Total HIV-1 DNA as the dependent variable
adjusting for the 3 clinical measures. Model B: N¼ 78, forward and backwards stepwise-optimized linear regression model with log10 Total HIV-1 DNA as the dependent variable, considering eight
immunological variables initially selected on the basis of having a positive correlation with Total DNA in the correlogram. Model C: N¼ 76, multivariable linear regression at baseline with log10
(Total HIV-1) as the dependent variable including clinical and immunological variables.
*b, regression coefﬁcients; s.e. and P values.
wExpression on T cells.
zNot selected for the ﬁnal optimized model.
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over 150 individuals with PHI correlated closely with Total
HIV-1 DNA levels, and we speculated that these might also be
predictors of time to viral rebound. Of note, T-cell immunity and
HIV-1 DNA are predictors of clinical progression, as determined
by CD4 T-cell count decline and viraemia11,18–20. However, these
associations did not persist in relation to predicting VL rebound,
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Table 3 | Baseline biomarkers predicting viral rebound after TI.
Biomarker expression on T cells
N¼20
Unadjusted
HR (CI) P-value
Adjusted for baseline HIV-1 DNA
HR (CI) P-value
Adjusted for week 48 HIV-1 DNA
HR (CI) P-value
PD-1 CD4þ 1.35 (1.07–1.71)
P¼0.011
1.46 (1.06–1.85)
P¼0.016
1.42 (1.10–1.84)
P¼0.0074
PD-1 CD8þ 1.15 (1.02–1.32)
P¼0.029
1.37 (0.96–1.35)
P¼0.15
1.15 (1.01–1.32)
P¼0.034
Tim-3 CD4þ 1.25 (1.12–1.40)
Po0.001
1.36 (1.16–1.60)
P¼0.009
1.27 (1.12–1.14)
Po0.001
Tim-3 CD8þ 1.11 (1.04–1.20)
P¼0.0036
1.15 (1.06–1.26)
P¼0.0011
1.11 (1.03–1.20)
P¼0.0034
Lag-3 CD4þ 1.08 (1.03–1.15)
P¼0.0036
1.082 (1.02–1.15)
P¼0.0066
1.09 (1.028–1.14)
P¼0.0035
Lag-3 CD8þ 1.104 (1.03–1.19)
P¼0.0093
1.129 (0.99–1.28)
P¼0.056
1.24 (1.02–1.24)
P¼0.015
CI, conﬁdence interval; HR, hazard ratio; TI, treatment interruption; VL, viral load.
Cox models reporting biomarkers measured at pre-therapy baseline (week 0) and time to plasma VL rebound (4400 copies per ml) after TI, 48 weeks later. Columns represent three models:
unadjusted, adjusting for baseline HIV-1 Total DNA and adjusting for week 48 HIV-1 Total DNA.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms9495
6 NATURE COMMUNICATIONS | 6:8495 | DOI: 10.1038/ncomms9495 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
suggesting that these two processes—time to rebound and time
to clinical progression—have different mechanisms. Indeed, in
SPARTAC, these two time intervals after TI did not
correlate (Supplementary Fig. 3). While there is plenty of
evidence to suggest that the progression is immune mediated, it
is increasingly proposed—and supported by mathematical
modelling21,22—that rebound is stochastic, or random23, that is,
the initiation of viral transcription in a latently infected cell at
levels adequate to result in plasma viraemia may not be initially
governed by the immune response.
These data suggest that the size of the reservoir is determined by
T-cell-mediated immunity in early HIV-1 infection, reﬂected in the
number of associations between HIV-1 DNA and immune
biomarkers at baseline. Once ART is commenced and viral
replication is suppressed, the CD4 T-cell count recovers and the
HIV-1 reservoir (in reality, an unknown entity for which we have
limited surrogate measures) declines. At the point of TI, two events
can occur. (i) viraemia returns; and (ii) absolute CD4 T-cell
numbers fall until a point at which ART needs to be reintroduced.
We hypothesize that these two processes are determined by
different mechanisms: (i) stochastic and dependent on the size of
the reservoir size; and (ii) mediated by HIV-1-speciﬁc immune
responses after viraemia has returned. Accordingly, it is possible
that studies describing T-cell-mediated mechanisms driving ‘elite
controllers’ may have little to offer our understanding of how to
induce PTC or HIV-1 cure. This model may be supported by our
ﬁnding that T-cell exhaustion markers at baseline (48 weeks prior
to TI) predict time to viral rebound, whereas the same markers
measured at the time of TI do not. (A caveat to this ﬁnding is that
different antibody clones were used for the surface ﬂuorescence-
activated cell sorting (FACS) staining at baseline and at week 48
and, due to the possibility of different afﬁnities, this is a possible
confounder which needs to be explored in future studies.)
The highly signiﬁcant impact of the markers PD-1, Tim-3 and
Lag-3 is intriguing, especially in view of the lack of association
for markers of activation (HLA-DR, CD38), which might be
expected to associate with rebound. PD-1 has been widely
reported to be upregulated on exhausted T cells in chronic viral
infections such as cytomegalovirus, simian immunodeﬁciency
virus (SIV) and HIV, in a process that is reversible through
blockade of PD-1 with its ligand. Accordingly, some investigators
have suggested that PD-1 is a marker of early exhaustion or even
activation—the latter being supported by its clustering with HLA-
DR and CD38 in the correlogram. Despite the identiﬁcation of
PD-1, Tim-3 and Lag-3 as potential biomarkers for viral rebound,
this does not in itself prove that they are mechanistic. There is
much interest in the therapeutic potential of blocking PD-1
(either directly or by antagonizing the PD-1 ligand), and even in
the context of targeting the HIV-1 reservoir. Of note, the
combination of anti-PD-1 (Nivolumab) and anti-CTLA-4
(Ipilimumab) monoclonal antibodies have shown encouraging
results in clinical trials in untreated melanoma24, and one might
speculate that this enhancement in T-cell function may also be
applicable for targeting the HIV-1 reservoir.
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Figure 4 | Co-expression of immune checkpoint markers. Data plots and Venn diagrams to show expression of one, two or three exhaustion markers
(Tim-3, Lag-3 and PD-1) at pre-therapy baseline on CD4 (n¼ 120) (a,b) and CD8 (n¼ 118) (c,d) T cells. Figures represent the percentage contribution to
different combinations of expression of the three markers with overall expression normalized to 100%.
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Tim-3 has been associated with T-cell exhaustion (loss of
functionality and decreased proliferation) in the context of HIV-1
infection25. Tim-3 expression on both CD4 and CD8 T cells is
elevated in HIVþ ve individuals compared with controls,
correlates with VL and is associated with disease progression.
As for PD-1, blocking the interaction of Tim-3 with its ligand can
restore functionality. Interestingly, in the same study it was
shown that PD-1 and Tim-3 identify distinct populations of cells,
rather than being co-expressed on the same dysfunctional
T cells, which we also found in our patients. This might help
explain why they both predict time to rebound and yet both are
not associated with HIV-1 DNA levels. Increased understanding
of which cells express these markers and how they contribute to
the HIV-1 reservoir could be important in developing new HIV-1
cure strategies. This will need to be addressed in larger studies
carefully designed for this purpose.
The role of Lag-3 (CD223) in HIV-1 infection is less clear,
although its upregulation has been associated with disease
progression and functional T-cell exhaustion26. Lag-3 is
structurally similar to the CD4 receptor and is a ligand for MHC
Class II, and part of the Ig superfamily on memory T cells27.
Mouse models have suggested some synergy between PD-1 and
Lag-3 (ref. 28), although it is interesting that we only ﬁnd limited
co-expression in our data. However, now that the proof-of-efﬁcacy
has been demonstrated in cancer trials for combination immune
checkpoint blockade24, it will be important to conduct further
studies to explore how this applies to HIV latency.
In summary, this analysis of SPARTAC participants under-
going TI after 48 weeks of ART reveals potential new biomarkers
that should be considered in larger studies exploring PTC.
The correlations between measures of T-cell-mediated immunity
and HIV-1 DNA prior to therapy make a case for the reservoir
size being determined by T-cell function early in infection.
The relationship between immune responses and the duration of
PTC at TI is much less clear, but the association with high levels
of T-cell exhaustion might help shed light on why some latently
infected cells reactivate and others do not. The work should help
in future studies to stratify patients for PTC, with the ultimate
aim to determine the mechanism of PTC, and identify new targets
for HIV-1 cure research.
Methods
Participants and trial design. SPARTAC10 was an international RCT enroling
adults with PHI within 6 months of a last negative, equivocal or incident HIV-1 test.
All participants gave written informed consent. Time of seroconversion was
estimated as the midpoint of last negative/equivocal and ﬁrst positive tests, or date of
incident test. Participants were randomized to receive ART for 48 weeks (ART-48),
12 weeks (ART-12) or no therapy (standard of care).
Participants for this sub-study were those infected with subtype B HIV-1 and
for whom adequate samples were available. For those in the analysis of viral
rebound at TI, we only considered participants in the ART-48 arm who had viral
load suppression (o50 HIV-1 copies per ml; Chiron bDNA, Bayer) at the point of
stopping ART (Table 1). Peripheral blood mononuclear cells (PBMC) were
available for analysis in all participants at baseline, regardless of treatment
allocation. Participants randomized to the ART-48 arm were sampled at week 48
immediately prior to TI. Viral remission was deﬁned as maintaining a HIV-1 RNA
viral load o400 copies per ml after stopping ART.
Ethics statement. The SPARTAC trial, and the immunological and virological
analyses performed in this study were approved by the following authorities: the
Medicines and Healthcare products Regulatory Agency (UK), the Ministry of
Health (Brazil), the Irish Medicines Board (Ireland), the Medicines Control
Council (South Africa) and the Uganda National Council for Science and Tech-
nology (Uganda). It was also approved by the following ethics committees in the
participating countries: the Central London Research Ethics Committee (UK),
Hospital Universita´rio Clementino Fraga Filho Ethics in Research Committee
(Brazil), the Clinical Research and Ethics Committee of Hospital Clinic in the
province of Barcelona (Spain), the Adelaide and Meath Hospital Research Ethics
Committee (Ireland), the University of Witwatersrand Human Research Ethics
Committee, the University of Kwazulu-Natal Research Ethics Committee and the
University of Cape Town Research Ethics Committee (South Africa), Uganda Virus
Research Institute Science and ethics committee (Uganda), the Prince Charles
Hospital Human Research Ethics Committee and St Vincent’s Hospital Human
Research Ethics Committee (Australia) and the National Institute for Infectious
Diseases Lazzaro Spallanzani, Institute Hospital and the Medical Research Ethics
Committee, and the ethical committee of the Central Foundation of San Raffaele,
MonteTabor (Italy). All participants signed a written informed consent.
Measurement of HIV-1 DNA. CD4 T cells were enriched from frozen PBMC
samples by negative selection (Dynabeads) to a purity of497%. CD4 T-cell DNA
was extracted (Qiagen) and used as input DNA for PCR. Cell copy number and
Total HIV-1 DNA levels were quantiﬁed in triplicate using previously published
assays29,30. Integrated HIV-1 was measured using an assay based on that previously
published31 but with some minor modiﬁcations as described elsewhere11.
Unspliced cell-associated HIV-1 RNA Transcript quantitation. RNA was
isolated using the Qiagen AllPrep DNA/RNA Mini kit as per the manufacturer’s
recommendations with the addition of an on-column double DNase digestion.
The RNA assay was a modiﬁed version of those previously described32–34. Brieﬂy,
complementary DNA was subjected to two rounds of PCR using semi-nested
primers. The ﬁrst reaction was a 15-cycle end-point reaction using MH535
(50-AACTAGGGAACCCACTGCTTAAG-30) and SL20 (50-TCTCCTTCTAGC
CTCCGCTAGTC-30) primers at a concentration of 400 nM each35 as previously
described32–34. The second reaction was a 40-cycle quantitative reaction
(forward primer 50-TAAAGCTTGCCTTGAGTGCT, SL20 and the probe
FAM—50-AGTRGTGTGTGCCCGTCTGTTG-30—BHQ-1), performed using a
Roche Lightcycler 480. The HIV standard was generated by in vitro transcribing
the plasmid Sp5-NL4.3 (generously provided by the lab of D. Purcell) using the
RiboMax Large Scale SP6 RNA production System (Promega). HIV RNA standards
were diluted in 10 ng ml 1 uninfected PBMC RNA. HIV measurements were
normalized to input cellular RNA using the 18S gene with the Ampliﬂuor Human/
Mouse 18S rRNA Primer Set (FAM labelled; Millipore, Cat No. SCR593). All
samples were negative when run without reverse transcriptase as a control.
CD8 and CD4 T-cell ELISpot assays. Quantiﬁcation of the HIV-1-speciﬁc CD8
response was performed by IFN-g ELISpot analysis20. Responses were determined
to subtype B consensus HIV-1 Gag overlapping peptides covering the entire Gag
protein (123 15mers overlapping by 11 amino acids; AIDS Research and Reference
Reagent Program, NIH). CD4 T-cell IFN-g ELISpot assays were carried out in real
time in UK subtype B participants on fresh blood samples. Methods are described
elsewhere, but essentially, CD4 T-cell frequencies against HIV-1 subtype B p24
were determined using IFN-g ELISpot using fresh CD8 T-cell-depleted PBMCs.
CD4 samples were analysed in duplicate and results were expressed as spot forming
units per 106 CD8-depleted peripheral blood leucocytes. ELISpot data analysis is
described elsewhere20.
Multiparameter FACS. Thawed PBMCs from healthy individuals (controls) and
HIV-1-infected patients (SPARTAC) were stained with two panels of antibodies. For
markers of activation, we used CD25 (PE, Miltenyi clone 3G10, 2ml per 50ml), CD38
(PE-Vio770; Miltenyi clone IB6, 1ml per 50ml), CD69 (FITC, Miltenyi clone FN50,
1ml per 50ml) and HLA-DR (PerCP, Miltenyi clone AC122, 1ml per 50ml). For
markers of exhaustion, we used Tim-3 (FITC, eBioscience clone F38-2E2; 0.05mg per
100ml), Lag-3 (PerCP-eF710, eBioscience clone 3D5223H, 0.024mg per 100ml), PD-1
(PE-Cy7, eBioscience clone eBioJ105, 0.2mg per 100ml) and TIGIT (PE, eBioscience
clone MBSA43, 0.05mg per 100ml). Both panels also included the anchor markers
CD3 (VioBlue, Miltenyi clone BW264/56, 0.5ml per 50ml), CD4 (VioGreen, Miltenyi
clone VIT4, 2ml per 50ml), CD8 (APC, Miltenyi cloneBW135/80, 1ml per 50ml) and
a Live/Dead marker, Near IR-APC-Cy7 (1:300 dilution). Cells were run on a
MAQSquant and analysed with FlowJO software. The gating strategy is present in
Supplementary Fig. 2. Results are reported throughout as percentages of cells
expressing the marker in question. Different antibody clones were used for the
surface FACS staining for Tim-3 (PE, R&D clone 344823, 0.05mg per 100ml), PD-1
(APC, eBiosciences clone MIH4, 0.5mg per 100ml) and Lag-3 (FITC, LifeSpan
Biosciences clone 17B4, 2mg per 100ml) at week 48 and, due to the possibility of
different afﬁnities, this is a possible confounder which needs to be explored in future
studies.
ELISAs. Interleukin-6 (IL-6) and D-dimer were quantiﬁed using commercial
assays (Quantikine HS600B IL-6 immunoassay (R&D Systems, Minneapolis,
Minnesota, USA) and Innovance D-dimer (Siemens Healthcare Diagnostics,
Tarrytown, New York, USA)), as described elsewhere36.
Statistical analysis. Tests between grouped variables and transformed log10 DNA
levels were performed using t-tests and linear regression. Differences between
HIV-1 DNA levels for individual HLA Class I alleles and other HLA alleles were
examined using Mann–Whitney tests. Comparisons of HIV-1 DNA levels between
patients carrying ‘protective’ and ‘progressive’ HLA alleles used t-tests. A
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correlogram15 was used to display the Pearson correlations between the
biomarkers. Variables with similar correlations are grouped together. The direction
and size of the correlations are illustrated by heat colour and pie charts. The order
of the biomarkers within the correlogram is determined by hierarchical clustering:
there are 2n-1 (217-1) possible orderings of the heat map, we use the optimal leaf
order algorithm16 to minimize the difference between adjacent biomarkers. The R
package correlogram was used to produce the image. Linear regression was carried
out between baseline HIV-1 Total DNA and variables selected from the
correlogram. The optimized multivariable model in Table 1B is constructed
stepwise in both directions to minimize AIC using the R step function. Time to
viral rebound was examined with Kaplan–Meier curves, and Cox proportional
hazards models. The proportional hazard assumption was tested by examining
Schoenfeld residuals using the cox.zph function from the R survival package. Time
to VL rebound was deﬁned as the time from TI (at week 48) to the ﬁrst of more
than one consecutive detectable VL4400 copies per ml. For T-cell exhaustion
markers, time to rebound was also analysed for 450 copies per ml. All statistics
were calculated using R version 3.1.0. Plots were drawn with R and Prism.
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